Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2018Website:
http://www.avrobio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/ADividend
Analysts recommendations
Institutional Ownership
Included in screeners
Similar companies
AVRO Latest News
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.
What type of business is AVROBIO?
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is AVROBIO in?
AVROBIO is in the Healthcare sector
What industry is AVROBIO in?
AVROBIO is in the Biotechnology industry
What country is AVROBIO from?
AVROBIO is headquartered in United States
When did AVROBIO go public?
AVROBIO initial public offering (IPO) was on 21 June 2018
What is AVROBIO website?
https://www.avrobio.com
Is AVROBIO in the S&P 500?
No, AVROBIO is not included in the S&P 500 index
Is AVROBIO in the NASDAQ 100?
No, AVROBIO is not included in the NASDAQ 100 index
Is AVROBIO in the Dow Jones?
No, AVROBIO is not included in the Dow Jones index
When was AVROBIO the previous earnings report?
No data
When does AVROBIO earnings report?
Next earnings report date is not announced yet